Abstract
The link of diabetes with co-occurring disorders in the brain involves complex and multifactorial pathways. Genetically engineered rodents that express familial Alzheimer’s disease-associated mutant forms of amyloid precursor protein and presenilin 1 (PSEN1) genes provided invaluable insights into the mechanisms and consequences of amyloid deposition in the brain. Adding diabetes factors (obesity, insulin impairment) to these animal models to predict success in translation to clinic have proven useful at some extent only. Here, we focus on contributing factors to diabetic brain injury with the aim of identifying appropriate animal models that can be used to mechanistically dissect the pathophysiology of diabetes-associated cognitive dysfunction and how diabetes medications may influence the development and progression of cognitive decline in humans with diabetes.
Original language | English |
---|---|
Pages (from-to) | 560-567 |
Number of pages | 8 |
Journal | Diabetes and Metabolism Journal |
Volume | 43 |
Issue number | 5 |
DOIs | |
State | Published - 2019 |
Bibliographical note
Publisher Copyright:Copyright © 2019 Korean Diabetes Association.
Funding
This research was supported by: National Institutes of Health AG057290, AG053999 and Alzheimer’s Association VMF-15-363458.
Funders | Funder number |
---|---|
Alzheimer’s Association, and Cure Alzheimer’s Fund | VMF-15-363458 |
Foundation for the National Institutes of Health | AG053999, AG057290 |
Keywords
- Dementia
- Diabetes mellitus
- Obesity
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism